Left: before statin treatment; right: same patient, one year after statin treatment. Photo: Harvard University
RPB-supported researchers at Massachusetts Eye and Ear/Harvard Medical School and scientists at University of Crete have conducted a phase I/II clinical trial investigating the efficacy of statins (cholesterol-lowering medications) for the treatment of patients with the dry form of age-related macular degeneration (AMD) — the leading cause of blindness in the developed world. Although effective treatments are available for the wet form of AMD, they are currently lacking for the more prevalent dry form.
The researchers found evidence that treatment with high-dose atorvastatin (80mg) is associated with regression of lipid deposits and improvement in visual acuity, without progression to advanced disease, in high-risk AMD patients.
February 5, 2016
The new way to measure ocular aging opens treatment avenues for numerous eye diseases.
The American Academy of Ophthalmology (AAO) and Research to Prevent Blindness (RPB) today announced the 2023 recipients of the RPB/AAO Award for IRIS Registry Research.
RPB acknowledges the passing of a dedicated former Board member.
Patricia Ann D’Amore, PhD, MBA, is recognized for ground-breaking contributions to the field of vision research.
Dr. Akrit Sodhi at Johns Hopkins Medicine has published a new study showing promise for an experimental treatment to prevent or slow vision loss in people with diabetes.
RPB launches awards in data science and Diabetic Eye Disease.
Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.
General Info | Grants | News & Resources |